Over the past two decades, biologics have transformed drug development 1 by targeting previously undruggable disease pathways
Mice treated with GLP-1 do not show a conditioned place preference to alcohol (Shirazi et al., 2013) and alcohol-preferring rats injected with EX4 reduce their operant responding for an alcohol solution (Davis et al., 2013)
phase 3 trials ongoing as of 2025 Best phase 2 weight loss (retatrutide) / 24.2% at 48 weeks, 12 mg dose Best phase 3 weight loss (tirzepatide) / 22.5% at 72 weeks, 15 mg dose Combination evidence / zero published controlled trials Primary combination risk / additive nausea, vomiting, potential pancreatitis Switching rationale / inadequate response or tolerability on tirzepatide Guideline position on combining / no major guideline endorses dual-incretin stacking What Are Mounjaro and Retatrutide, and How Do They Differ
Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice
If you are considering this treatment, consult with Dr
B was HBTU, HATU, TBTU, PyAOP, or PyBOP